康柏西普玻璃体腔注射治疗CRVO继发黄斑水肿的临床研究  

Clinical Study of Intravitreal Injection of Conbercept in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion

作　　者：郑盼盼[1] 姜涛[1] 于梦丹 王焕霞[1] 杨丛丛[1] 

机构地区：[1]青岛大学附属医院眼科,山东青岛266003

出　　处：《中国继续医学教育》2016年第31期154-156,共3页China Continuing Medical Education

摘　　要：目的探讨玻璃体腔内注射康柏西普治疗视网膜中央静脉阻塞继发黄斑水肿的效果。方法选取2015年4-10月在我院经临床诊断为视网膜中央静脉阻塞继发黄斑水肿的患者15例（15眼）,回顾性研究,观察记录注射后前后患者的最佳矫正视力（Best-Corrected Visual Acuity,BCVA）、眼压、黄斑中心凹的视网膜厚度（Central Macular Thickness,CMT）。同时采用配对t检验对BCVA和CMT进行统计学分析。结果全部患者玻璃体腔内注射康柏西普后最佳矫正视力均有不同程度的提高,眼部OCT显示黄斑中心凹的视网膜厚度（CMT）明显变薄,差异有统计学意义（P〈0.05）。在整个随访过程中,黄斑水肿复发经再次注射后CMT降低。结论玻璃体腔内注射康柏西普治疗CRVO继发黄斑水肿,中心视力有所提高,黄斑水肿减轻。复发患者需再次注射,仍可有明显改善。Objective To observe the efficacy of conbercept in the treatment of macular edema secondary to central retinal vein occlusion. Methods To be a retrospective study, 15 eyes of 15 patients with macular edema secondary to central retinal vein occlusion in our hospital from April 2015 to October 2015 were selected. The best corrected visual acuity（BCVA）, intraocular pressure and central macular thickness（CMT：by optical coherence tomography） of after injection were recorded, and compared with pretherapy. BCVA and CMT were statistically analyzed by paired test. Results Best corrected visual acuity of all patients were improved after intravitreal injection of Conbercept,The CMT was thinner than prior treatment, statistical analysis was significant（P0.05）. In the whole process, the macular edema of some patients would be return, it was still decreased after reinjection. Conclusion Intravitreal injection of Conbercept improves visual acuity and relieves macular edema secondary to CRVO. But the macular edema of some patients would be relapse later,they should be reinjection and become better again.

关 键 词：视网膜中央静脉阻塞 康柏西普 黄斑水肿 

分 类 号：R774.5[医药卫生—眼科]